Clinical practice guidelines aim to reduce the rates of peritoneal dialysis (PD)-related infections, a common complication of PD in end-stage kidney disease patients. We describe the clinical practices used by Australian and New Zealand nephrologists to prevent PD-related infections in PD patients.
Methods
A survey of PD practices in relation to the use of antibiotic and antifungal prophylaxis in PD patients was conducted of practicing nephrologists identified via the Australia and New Zealand Society of Nephrology (ANZSN) membership in 2013.
Results
Of 333 nephrologists approached, 133 (39.9%) participated. Overall, 127 (95.5%) nephrologists prescribed antibiotics at the time of Tenckhoff catheter insertion, 85 (63.9%) routinely screened for nasal S. aureus carriage, with 76 (88.4%) reporting they treated S. aureus carriers with mupirocin ointment. Following Tenckhoff catheter insertion, 79 (59.4%) prescribed mupirocin ointment at the exit site or intranasally, and 93 (69.9%) nephrologists routinely prescribed a course of oral antifungal agent whenever their PD patients were given a course of antibiotics.
Conclusions
Although the majority of nephrologists prescribe antibiotics at the time of Tenckhoff catheter insertion, less than 70% routinely prescribe mupirocin ointment and/or prophylactic antifungal therapy. This variation in practice in Australia and New Zealand may contribute to the disparity in PD-related infection rates that is seen between units.
WoodrowG., TurneyJ.H., BrownjohnA.M.Technique failure in peritoneal dialysis and its impact on patient survival.Perit Dial Int1997; 17(4): 360–4.
2.
GolperT.A., BrierM.E., BunkeM., SchreiberM.J., BartlettD.K., HamiltonR.W.Risk factors for peritonitis in long-term peritoneal dialysis: the Network 9 peritonitis and catheter survival studies. Academic Subcommittee of the Steering Committee of the Network 9 Peritonitis and Catheter Survival Studies.Am J Kidney Dis1996; 28(3): 428–36.
3.
FriedL.Mortality in peritoneal dialysis patients.ASAIO J1999; 45(6): 526–30.
4.
MujaisS.Microbiology and outcomes of peritonitis in North America.Kidney Int Suppl2006; (103): S55–62.
5.
JoseM.D., JohnsonD.W., MudgeD.W., TranaeusA., VossD., WalkerR.Peritoneal dialysis practice in Australia and New Zealand: a call to action.Nephrology2011; 16(1): 19–29.
6.
PirainoB., BernardiniJ., BrownE., FigueiredoA., JohnsonD.W., LyeW-CISPD position statement on reducing the risks of peritoneal dialysis-related infections.Perit Dial Int2011; 31(6): 614–30.
7.
BoudvilleN., DentH., McDonaldS., HurstK., ClaytonP.Peritoneal Dialysis. In: ClaytonP., McDonaldS., HurstK., eds. ANZDATA Registry Report 2013.Adelaide, South Australia: Australia and New Zealand Dialysis and Transplant Registry2014: 1–31.
8.
StrippoliG.F.M., TongA., JohnsonD., SchenaF.P., CraigJ.C.Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients.Cochrane Database Syst Rev2004 (4): CD004679.
9.
LuzarM.A., BrownC.B., BalfD., HillL., IssadB., MonnierB.Exit-site care and exit-site infection in continuous ambulatory peritoneal dialysis (CAPD): results of a randomized multicenter trial.Perit Dial Int1990; 10(1): 25–9.
10.
van DiepenA.T.N., TomlinsonG.A., JassalS.V.The association between exit-site infection and subsequent peritonitis among peritoneal dialysis patients.CJASN2012; 7(8): 1266–71.
11.
MilesR., HawleyC.M., McDonaldS.P., BrownF.G., RosmanJ.B., WigginsK.J.Predictors and outcomes of fungal peritonitis in peritoneal dialysis patients.Kidney Int2009; 76(6): 622–8.
12.
BadveS., SmithA., HawleyC., JohnsonD.Adherence to guideline recommendations for infection prophylaxis in peritoneal dialysis patients [letter].Nephrol Dial Transplant Plus2009; 2: 508.
13.
GhaliJ.R., BannisterK.M., BrownF.G., RosmanJ.B., WigginsK.J., JohnsonD.W.Microbiology and outcomes of peritonitis in Australian peritoneal dialysis patients.Perit Dial Int2011; 31(6): 651–62.
MudgeD.W., BoudvilleN., BrownF., ClaytonP., DuddingtonM., HoltS.Peritoneal dialysis practice in Australia and New Zealand: a call to sustain the action.Nephrology2016; 21(7): 535–46.
16.
EvansL.M.Peritoneal dialysis: one unit's response to improving outcome and technique survival.RSAJ2012; 8(3): 114–9.
17.
WongS.S.H., ChuK.H., CheukA., TsangW.K., FungS.K.S., ChanH.W.H.Prophylaxis against gram-positive organisms causing exit-site infection and peritonitis in continuous ambulatory peritoneal dialysis patients by applying mupirocin ointment at the catheter exit site.Perit Dial Int2003; 23(Suppl 2): S153–8.
ChalkiadakisG.E., GonnianakisC., TsatsakisA., TsakalofA., MichalodimitrakisM.Preincisional single-dose ceftriaxone for the prophylaxis of surgical wound infection.Am J Surg1995; 170(4): 353–5.
21.
KowL., ToouliJ., BrookmanJ., McDonaldP.J.Comparison of cefotaxime plus metronidazole versus cefoxitin for prevention of wound infection after abdominal surgery.World J Surg1995; 19(5): 680–6; discussion 6.
22.
LeaperD., Burman-RoyS., PalancaA., CullenK., WorsterD., Gautam-AitkenE.Prevention and treatment of surgical site infection: summary of NICE guidance.BMJ2008; 337: a1924.
23.
ClassenD.C., EvansR.S., PestotnikS.L., HornS.D., MenloveR.L., BurkeJ.P.The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection.N Engl J Med1992; 326(5): 281–6.
24.
GuptaB., BernardiniJ., PirainoB.Peritonitis associated with exit site and tunnel infections.Am J Kidney Dis1996; 28(3): 415–9.
25.
DaveyP., CraigA.M., HauC., MalekM.Cost-effectiveness of prophylactic nasal mupirocin in patients undergoing peritoneal dialysis based on a randomized, placebo-controlled trial.J Antimicrob Chemother1999; 43(1): 105–12.
26.
LauplandK.B., ConlyJ.M.Treatment of Staphylococcus aureus colonization and prophylaxis for infection with topical intranasal mupirocin: an evidence-based review.Clin Infect Dis2003; 37(7): 933–8.
27.
The Mupirocin Study Group.Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis.J Am Soc Nephrol1996; 7(11): 2403–8.
28.
BernardiniJ., PirainoB., HolleyJ., JohnstonJ.R., LutesR.A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin.Am J Kidney Dis1996; 27(5): 695–700.
29.
XuG., TuW., XuC.Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis.Nephrol Dial Transplant2010; 25(2): 587–92.
30.
JohnsonD.W., BadveS.V., PascoeE.M., BellerE., CassA., ClarkC.Antibacterial honey for the prevention of peritoneal-dialysis-related infections (HONEYPOT): a randomised trial.Lancet Infect Dis2014; 14(1): 23–30.
31.
ZhangL., BadveS.V., PascoeE.M., BellerE., CassA., ClarkC.The effect of exit-site antibacterial honey versus nasal mupirocin prophylaxis on the microbiology and outcomes of peritoneal dialysis-associated peritonitis and exit-site infections: a sub-study of the Honeypot Trial.Perit Dial Int2015; 35(7): 712–21.
32.
Kopriva-AltfahrtG., KonigP., MundleM., PrischlF., RoobJ.M., WiesholzerM.Exit-site care in Austrian peritoneal dialysis centers—a nationwide survey.Perit Dial Int2009; 29(3): 330–9.
33.
LoW.K., ChanC.Y., ChengS.W., PoonJ.F., ChanD.T., ChengI.K.A prospective randomized control study of oral nystatin prophylaxis for Candida peritonitis complicating continuous ambulatory peritoneal dialysis.Am J Kidney Dis1996; 28(4): 549–52.
34.
RestrepoC., ChaconJ., ManjarresG.Fungal peritonitis in peritoneal dialysis patients: successful prophylaxis with fluconazole, as demonstrated by prospective randomized control trial. [Erratum appears in Perit Dial Int 2011; 31(2):120].Perit Dial Int2010; 30(6):619–25.
35.
ProwantB.F., WaradyB.A., NolphK.D.Peritoneal dialysis catheter exit-site care: results of an international survey.Perit Dial Int1993; 13(2): 149–54.
36.
WilkieM., WildJ.Peritoneal dialysis access—results from a UK survey.Perit Dial Int2009; 29(3): 355–7.
37.
BonucchiD., D'AmelioA., CapelliG., AlbertazziA.Management of vascular access for dialysis: an Italian survey.Nephrol Dial Transplant1999; 14(9): 2116–8.
38.
CabanaM.D., RandC.S., PoweN.R., WuA.W., WilsonM.H., AbboudP.A.Why don't physicians follow clinical practice guidelines? A framework for improvement.JAMA1999; 282(15): 1458–65.
39.
WoolfS.H.Practice guidelines: a new reality in medicine. III. Impact on patient care.Arch Intern Med1993; 153(23): 2646–55.
40.
HaywardR.S., GuyattG.H., MooreK.A., McKibbonK.A., CarterA.O.Canadian physicians’ attitudes about and preferences regarding clinical practice guidelines.CMAJ1997; 156(12): 1715–23.
41.
GrimshawJ.M., Shirr anL., ThomasR., MowattG., FraserC., BeroL.Changing provider behavior: an overview of systematic reviews of interventions.Med Care2001; 39(Suppl 2): II2–45.
42.
WilkieM.Are quality improvement collaboratives the way forward in peritoneal dialysis?Perit Dial Int2016; 36(1): 3–4.
